Alloy vs Brightmeds
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alloy
Best for women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directoryStarting at $80/mo
Brightmeds
Best for Patients who want access to both compounded GLP-1s (semaglutide / tirzepatide standard + microdosing) AND brand-name FDA-approved Zepbound® (pens and vials) through a single telehealth platform with a clinician approval guarantee, and who are comfortable signing up to see pricing.Side-by-Side Comparison
| Feature | Alloy | Brightmeds |
|---|---|---|
| Overall Score | ✓7.4/10 | 6.8/10 |
| Starting Price | $80/mo | — |
| Editorial Rating | ✓3.7 ★ /5 | 3.4 ★ /5 |
| Features | 8 features | ✓11 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Alloy
Pros
- ✓Broadest GLP-1 formulary in our catalog: brand Wegovy + brand Zepbound + oral Wegovy + compounded semaglutide + compounded tirzepatide + compounded liraglutide
- ✓All consulting doctors are certified by The Menopause Society — only ~1,000 such certified practitioners exist among ~20,000 OB-GYNs in the US
- ✓Brand-name Wegovy starting at $199/mo and compounded liraglutide starting at $80/mo cover both ends of the price/access spectrum
- ✓STARTGLP1 promo code knocks $50 off the first month per the public site
Cons
- ✗Not available in Louisiana or Mississippi (verified) — readers in those two states should be routed elsewhere
- ✗Initial consultation is $49 and is separate from medication cost — readers should know there's a non-refundable upfront fee
- ✗Menopause-specialty framing — best fit for women in menopause/perimenopause, not the right product for men or younger women whose primary need is weight loss
Brightmeds
Pros
- ✓Offers BOTH compounded and brand-name FDA-approved Zepbound® (pens + vials) — rare dual-modality access in DTC market
- ✓Microdosing protocols available for both compounded semaglutide and tirzepatide — appeals to titration-sensitive patients
- ✓Verbatim FDA compounded-medication disclaimer published with explicit 503A and 503B facility mention — uncommon transparency
- ✓Money-back guarantee if not approved by clinician
- ✓Trustpilot social proof: 4.8/5 from 800+ reviews (per site claim — not independently verified here)
- ✓Broader product range than typical DTC GLP-1 marketplace
Cons
- ✗Pricing NOT disclosed on homepage — gated behind product pages or application flow
- ✗Pharmacy partner NOT named — only 'certified U.S. pharmacies' generic framing
- ✗LegitScript certification NOT mentioned on the homepage
- ✗Named medical director NOT disclosed
- ✗Full states-served list NOT disclosed
- ✗Corporate legal entity (LLC/Inc/PC) NOT disclosed
- ✗Governing law / arbitration venue NOT specified
- ✗Ongoing cancellation policy (post-approval) NOT detailed publicly
- ✗Trustpilot rating claim NOT independently audited in this verification pass
Our Verdict
Alloy edges out Brightmeds with a higher overall score of 7.4/10 and is particularly strong for women in menopause/perimenopause who want a Menopause Society-certified clinician AND the broadest brand+compounded GLP-1 formulary in our directory. Brightmeds remains a solid alternative, especially if you're looking for Patients who want access to both compounded GLP-1s (semaglutide / tirzepatide standard + microdosing) AND brand-name FDA-approved Zepbound® (pens and vials) through a single telehealth platform with a clinician approval guarantee, and who are comfortable signing up to see pricing..
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.